DNA polymerase epsilon, catalytic subunitGenealiases: CRCS12 · FILS · IMAGEI · POLE1
Q-omics provides the consensus-scored POLE profile across patient tissues and cancer cell-line models. POLE expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, POLE is differentially expressed in 14, with the highest sampling consensus in KIRP. Additionally, POLE protein abundance shows 25,929 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, KIRP, and LSCC as cancer lineages where POLE shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POLE — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POLE survival associations across molecular data types. POLE RNA expression shows survival associations in the most cancer types (27), followed by mutation status (12) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POLE RNA expression–survival associations across cancer types. High POLE expression shows unfavorable associations in ACC, MESO, KIRC, KICH and UVM, but favorable associations in SCLC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for POLE RNA expression.
This table summarizes POLE tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for POLE. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POLE shows higher tumor expression in KIRP, BLCA, HNSC, KIRC, COAD and LUSC. The KIRP box plot shows higher POLE RNA expression in tumor versus normal tissue (log2 FC = +1.740, t-test p < 0.001).
This table shows molecular features associated with POLE in patient tissues and cancer cell lines. In patient samples, POLE shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, POLE RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
